About: Role for Anti-Cytokine Therapies in Severe Coronavirus Disease 2019

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Role for Anti-Cytokine Therapies in Severe Coronavirus Disease 2019 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Role for Anti-Cytokine Therapies in Severe Coronavirus Disease 2019
Creator	Abbate, Antonio Alahmed, Abdullah Buckley, Leo Devlin, John George, ; Libby, ; Ting, Clara Van Tassell, Benjamin Wohlford, F
Source	Medline; PMC
abstract	The causative agent for coronavirus disease 2019, severe acute respiratory syndrome coronavirus 2, appears exceptional in its virulence and immunopathology. In some patients, the resulting hyperinflammation resembles a cytokine release syndrome. Our knowledge of the immunopathogenesis of coronavirus disease 2019 is evolving and anti-cytokine therapies are under active investigation. This narrative review summarizes existing knowledge of the immune response to coronavirus infection and highlights the current and potential future roles of therapeutic strategies to combat the hyperinflammatory response of patients with coronavirus disease 2019. DATA SOURCES: Relevant and up-to-date literature, media reports, and author experiences were included from Medline, national newspapers, and public clinical trial databases. STUDY SELECTION: The authors selected studies for inclusion by consensus. DATA EXTRACTION: The authors reviewed each study and selected approrpriate data for inclusion through consensus. DATA SYNTHESIS: Hyperinflammation, reminiscent of cytokine release syndromes such as macrophage activation syndrome and hemophagocytic lymphohistiocytosis, appears to drive outcomes among adults with severe coronavirus disease 2019. Cytokines, particularly interleukin-1 and interleukin-6, appear to contribute importantly to such systemic hyperinflammation. Ongoing clinical trials will determine the efficacy and safety of anti-cytokine therapies in coronavirus disease 2019. In the interim, anti-cytokine therapies may provide a treatment option for adults with severe coronavirus disease 2019 unresponsive to standard critical care management, including ventilation. CONCLUSIONS: This review provides an overview of the current understanding of the immunopathogenesis of coronavirus disease 2019 in adults and proposes treatment considerations for anti-cytokine therapy use in adults with severe disease.
has issue date	2020-08-10(xsd:dateTime)
bibo:doi	10.1097/cce.0000000000000178
bibo:pmid	32832913
has license	cc-by-nc-nd
sha1sum (hex)	dfce6080f7b8feebb10bbdd76bd06d0d04107e02
schema:url	https://doi.org/10.1097/cce.0000000000000178
resource representing a document's title	Role for Anti-Cytokine Therapies in Severe Coronavirus Disease 2019
has PubMed Central identifier	PMC7419062
has PubMed identifier	32832913
schema:publication	Crit Care Explor
resource representing a document's body	covid:dfce6080f7b8feebb10bbdd76bd06d0d04107e02#body_text
is schema:about of	named entity 'Disease' named entity 'COVID' named entity 'monoclonal antibodies' named entity 'control group' named entity 'cytokine release syndrome' named entity 'critically ill' named entity 'anakinra' named entity 'infection' named entity 'anakinra' named entity 'alveolar macrophages' named entity 'COVID' named entity 'immunosuppressive' named entity 'dexamethasone' named entity 'risk of death' named entity 'IL-1β' named entity 'CD4+ T cells' named entity 'Anakinra' named entity 'oxygen' named entity 'monoclonal antibodies' named entity 'inflammasome' named entity 'sepsis' named entity 'IL-6' named entity 'cytokine' named entity 'bwh' named entity 'Pharmacology' named entity 'half-lives' named entity 'anti-inflammatory' named entity 'critically ill' named entity 'CD147' named entity 'interleukin' named entity 'sepsis' named entity 'COVID' named entity 'tumor necrosis factor-α' named entity 'IL-1β' named entity 'multiprotein complex' named entity 'tumor necrosis factor-α' named entity 'fusion protein' named entity 'SARS-CoV-1' named entity 'tumor necrosis factor-α' named entity 'observational studies' named entity 'COVID' named entity 'ADAM17' named entity 'adhesion molecule' named entity 'COVID-19' named entity 'hypoxemia' named entity 'COVID-19' named entity 'hepatobiliary' named entity 'systemic inflammation' named entity 'National Institutes of Health' named entity 'Middle East respiratory syndrome coronavirus' named entity 'IL-1' named entity 'infection' named entity 'COVID' named entity 'transaminase' named entity 'mm Hg' named entity 'COVID' named entity 'case series' named entity 'SARS-CoV-2' named entity 'onset of action' named entity 'IL-6' named entity 'triglyceride levels' named entity 'ARDS' named entity 'absolute risk' named entity 'COVID-19' named entity 'COVID-19' named entity 'chemokine' named entity 'IL-10' named entity 'Renal impairment' named entity 'IL-1β' named entity 'cytochrome P450' named entity 'IL-6' named entity 'canakinumab' named entity 'SARS-CoV-2'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software